Video

Dr. Schmidt on the Clinical Implications of AMG 420 in Multiple Myeloma

Timothy M. Schmidt, MD, discusses the clinical implications of AMG 420 in multiple myeloma.

Timothy M. Schmidt, MD, an assistant professor in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses the clinical implications of AMG 420 in multiple myeloma.

AMG 420 demonstrated proof of concept for using bispecific antibodies in multiple myeloma, says Schmidt. The agent showed remarkable responses with a significant depth and durability of response.

However, because of the design of the drug’s linker, AMG 420 has a short half-life and is metabolized quickly by the patient, Schmidt says. As such, treatment with the agent requires continuous infusion via a pump. Although feasible, this method of administration is not convenient for patients or providers, Schmidt explains. Novel bispecific antibodies being developed may be able to overcome this limitation, concludes Schmidt.

Related Videos
Rene Y. McNall-Knapp, MD, pediatric hematologist-oncologist, Jimmy Everest Center, Oklahoma Children’s Hospital OU Health; professor, Department of Pediatrics, University of Oklahoma Health Sciences Center
John Andrew Livingston, MD, MS
Howard Colman, MD, PhD, Jan M. Huntsman Presidential Professor, Department of Neurosurgery, member, Brain Tumor Research Team, and leader, Center for Neurologic Cancers, Huntsman Cancer Institute, University of Utah
Kathleen N. Moore, MD, MS
Rona Yaeger, MD
 PER® International Symposium on Melanoma and Other Cutaneous Malignancies
Robert
Charles B. Nguyen, MD
YI LIN, MD, PHD
Dr Fakih on the FDA Approval of Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC